Charles River, Valo Health announce strategic partnership

By The Science Advisory Board staff writers

January 20, 2022 -- Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence (AI)-enabled drug discovery and development platform.

The collaboration intends to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences, the companies said. The partnership's combined offerings will utilize Valo's Opal platform for small molecule development, which leverages a "closed-loop," in-silico experimental platform that rapidly iterates using program data to identify novel compounds, and Charles River's capabilities in discovery optimization -- including medicinal chemistry, absorption, distribution, metabolism and excretion, biology, pharmacology, and, ultimately, safety testing and investigational new drug submission.

The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River.

No financial details were disclosed.

Charles River to partner with ATEM Structural Discovery
Charles River Laboratories International has inked a partnership with ATEM Structural Discovery to provide its clients with ATEM's cryoelectron microscopy...
Jackson Laboratory acquires Charles River Laboratories Japan
Biomedical research company the Jackson Laboratory has acquired Charles River Laboratories Japan's Research Models and Services business as a wholly owned...
Charles River reports 34% revenue spike in Q2
Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.
Charles River completes Vigene acquisition
Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter